Harmine HCl
MAO-A and DYRK inhibitor / Selective competitive and reversible inhibitor of MAO-A (IC50 = 8 µM).1 Harmine is a potent and specific inhibitor of both the kinase activity and autophosphorylation of tyrosine during translation DYRK1A (IC50’s: DYRKA1A = 33 nM; DYRKA1B = 166 nM; DYRK2 = 1.9 µM; DYRK4 = 80 µM).2,3 Inhibits self-renewal and promotes differentiation of glioblastoma stem-like cells(GSLC’s) possibly via inhibition of Akt phosphorylation.4 Harmine has also been shown to possess antimicrobial, antifungal, antiplasmodial, antitumor, antioxidant, antimutagenic and antigenotoxic properties.5 Inhibits osteoclast differentiation and bone resorption via downregulation of c-Fos and NFATc1 induced by RANKL.6
Biochemicals & reagents
343-27-1
1) Wouters (1998) Structural Aspects of Monoamine Oxidase and its Reversible Inhibition Current Medicinal Chemistry 5 137 2) Seifert et al. (2008) DYRK1A phosphorylates caspase 9 at an inhibitory site and is potentnly inhibited in human cells by harmine FEBS J. 275 6268 3) Gockler et al. (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite outgrowth FEBS J. 276 6324 4) Liu et al. (2013) Harmine hydrochloride inhibits Akt phosphorylation and depletes the pool of cancer stem-like cells of gliobalstoma J.Neurooncol. 112 39 5) Patel et al. (2012) A review on medical importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid “Harmine” Asian Pac.J.Trop.Biomed. 2 660 6) Yoneazwa et al. (2011) Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo. Eur.J.Pharmacol. 650 511
-20°C
TARGET: Monoamine oxidase; Serotonin; Dopamine -- PATHWAY: Redox; AKT -- RESEARCH AREA: Neuroscience; Cancer stem cells -- DISEASE AREA: Infectious disease; Parasites